World's Best Scientists 2026 revealed!
Andrea Ardizzoni

Andrea Ardizzoni

D-Index & Metrics

Medicine

D-Index
78
Citations
23450
World Ranking
18003
National Ranking
728

Overview

Andrea Ardizzoni is affiliated with the University of Bologna in Italy and focuses primarily on research within the field of Medicine, with a particular emphasis on Oncology. Their work extensively covers subfields such as Pulmonary and Respiratory Medicine, Epidemiology, Molecular Biology, and Surgery.

The scientist has contributed significantly to several main research topics, including:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Diagnosis and Treatment
  • Peptidase Inhibition and Analysis
  • Neuroendocrine Tumor Research Advances

Their publication record shows multiple papers in prominent journals. Among the most recent notable papers are:

  • "Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", 2021, Annals of Oncology
  • "First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC", 2023, New England Journal of Medicine
  • "Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial", 2020, ESMO Open
  • "ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data", 2020, Lung Cancer
  • "CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations", 2020, European Journal of Cancer

The frequent co-authors associated with Andrea Ardizzoni include:

  • Francesco Gelsomino
  • Alessandro Di Federico
  • Andrea De Giglio
  • Francesca Sperandi
  • Filippo Gustavo Dall'Olio

The majority of their work has been published in key academic venues such as:

  • Annals of Oncology
  • Journal of Thoracic Oncology
  • Cancers
  • Journal of Clinical Oncology
  • European Journal of Cancer

Overall, Andrea Ardizzoni's research contributions focus on advancing understanding and treatment methodologies in oncology, with a strong concentration on lung and colorectal cancer studies, immunotherapy, and clinical outcomes related to cancer treatments.

Best Publications

  • Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

    Antonino Musolino;Nadia Naldi;Beatrice Bortesi;Debora Pezzuolo

  • JC‐1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess ΔΨ changes in intact cells: implications for studies on mitochondrial functionality during apoptosis

    Stefano Salvioli;Andrea Ardizzoni;Claudio Franceschi;Andrea Cossarizza

  • Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non–Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis

    Andrea Ardizzoni;Luca Boni;Marcello Tiseo;Frank V. Fossella

  • Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

    Andrea Ardizzoni;Heine Hansen;Per Dombernowsky;Teresa Gamucci

  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  • Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

    Jean Charles Soria;Enriqueta Felip;Manuel Cobo;Shun Lu

  • Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer

    U Gatzemeier;G Groth;C Butts;N Van Zandwijk

  • Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

    R. Rosell;U. Gatzemeier;D. C. Betticher;U. Keppler

  • Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.

    John R. Eckardt;Joachim von Pawel;Jean-Louis Pujol;Zsolt Papai

  • Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

    A.-M.C. Dingemans;M. Früh;A. Ardizzoni;B. Besse

  • Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel

    Cesare Gridelli;Matti Aapro;Andrea Ardizzoni;Lodovico Balducci

  • Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

    G. Giaccone;A. Ardizzoni;A. Kirkpatrick;M. Clerico

  • Grading the neuroendocrine tumors of the lung: an evidence-based proposal

    G Rindi;C Klersy;F Inzani;G Fellegara

  • Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value.

    Giulia Mazzaschi;Denise Madeddu;Angela Falco;Giovanni Bocchialini

  • Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: Results of an European Experts Panel

    C. Gridelli;A. Ardizzoni;T. Le Chevalier;C. Manegold

  • ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 Mg or 600 Mg, Taken With a Low-Fat Meal Versus 750 Mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)

    Byoung Chul Cho;Dong Wan Kim;Alessandra Bearz;Scott A. Laurie

  • Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

    C Bozzetti;F V Negri;C A Lagrasta;P Crafa

  • Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

    Lucia Del Mastro;Sabino De Placido;Paolo Bruzzi;Michele De Laurentiis

  • Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.

    Antonino Musolino;Laura Ciccolallo;Michele Panebianco;Elisa Fontana

  • Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

    Jean-Charles Soria;Soria Jean-Charles;Enriqueta Felip;Felip Enriqueta

Frequent Co-Authors

Pierfranco Conte
Pierfranco Conte University of Padua
Enriqueta Felip
Enriqueta Felip Vall d'Hebron Institut de Recerca
Filippo De Marinis
Filippo De Marinis European Institute of Oncology
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Pieter E. Postmus
Pieter E. Postmus Leiden University Medical Center
Paolo Bruzzi
Paolo Bruzzi Ospedale San Martino
Byoung Chul Cho
Byoung Chul Cho Yonsei University
Guido Rindi
Guido Rindi Catholic University of the Sacred Heart
Shirish M. Gadgeel
Shirish M. Gadgeel University of Michigan–Ann Arbor
Federico Cappuzzo
Federico Cappuzzo Azienda Unità Sanitaria Locale Della Romagna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in Medicine opens up diverse educational and career options beyond the traditional MD route. Many students start their healthcare careers with lpn online programs, which offer flexible, accessible training for those seeking to enter the field quickly. These programs can serve as stepping stones to advanced nursing roles or further medical study.

For those interested in mental health, pursuing the shortest pmhnp program online can lead to a career as a Psychiatric Mental Health Nurse Practitioner. This path allows students to complete their education faster and begin addressing critical mental health needs in their communities sooner.

Alternatively, if you’re drawn to the management side of healthcare, consider health administration degrees online. These programs blend healthcare knowledge with business and leadership skills, preparing graduates for important non-clinical roles in hospitals and healthcare organizations.

Those looking to advance further may pursue a master’s degree. The masters in healthcare administration cost can vary widely, but affordable online options make this advanced credential more accessible than ever. With the right program, you can build a rewarding career while managing tuition costs responsibly.

Best Scientists Citing Andrea Ardizzoni

Trending Scientists